{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:10:48Z","timestamp":1792843848535,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370210"],"award-info":[{"award-number":["82370210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370210"],"award-info":[{"award-number":["82370210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370210"],"award-info":[{"award-number":["82370210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2021-I2M1-040"],"award-info":[{"award-number":["CIFMS 2021-I2M1-040"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2021-I2M1-040"],"award-info":[{"award-number":["CIFMS 2021-I2M1-040"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2021-I2M1-040"],"award-info":[{"award-number":["CIFMS 2021-I2M1-040"]}]},{"name":"the Guizhou Science and Technology Department of China","award":["GCC[2022]030-1"],"award-info":[{"award-number":["GCC[2022]030-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Maintaining protein homeostasis is vital for multiple myeloma (MM) cell survival. Indirubin- 3-monoxime (I3MO), a potential MM therapeutic, inhibits proteasome activity, while histone deacetylase 6 (HDAC6) regulates autophagy. We developed I3MV- 8b, an I3MO derivative, integrating an HDAC6 inhibitor moiety to enhance dual inhibition of proteasome and autophagy pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The anti-MM effects of I3MV- 8b were tested in vitro and in vivo. To identify downstream targets, RNA-seq and dual-luciferase reporter assays were performed. Additionally, ChIP-seq and IP-MS techniques were employed to elucidate the underlying molecular mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>I3MV- 8b significantly suppressed MM cell proliferation and induced apoptosis. Combined with proteasome inhibitors, I3MV- 8b enhanced cytotoxicity by concurrently inhibiting proteasome and autophagy pathways. It reduced TRIM28 transcription, correlating with lower expression of proteasome subunits and autophagy-related genes. ChIP-seq revealed that TRIM28 binds to proteasome gene promoters, and its knockdown decreased proteasome subunit expression and activity. TRIM28 knockdown also impaired autophagosome formation. IP-MS and Co-IP assays showed TRIM28 interacted with 14\u20133 -\u20093\u03b6, a negative regulator of autophagy, promoting its ubiquitination and degradation. This interaction reduced autophagy regulation, further sensitizing cells to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>I3MV- 8b offers a novel dual inhibition strategy targeting proteasome and autophagy, presenting a promising therapeutic option for MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-025-00773-3","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T16:19:14Z","timestamp":1744042754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28"],"prefix":"10.1186","volume":"13","author":[{"given":"Teng","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"9983","key":"773_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385(9983):2197\u2013208.","journal-title":"Lancet"},{"issue":"22","key":"773_CR2","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","volume":"22","author":"SK Kumar","year":"2016","unstructured":"Kumar SK, Anderson KC. Immune therapies in multiple myeloma. Clin Cancer Res. 2016;22(22):5453\u201360.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"773_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","volume":"69","author":"N Nikesitch","year":"2016","unstructured":"Nikesitch N, Ling SC. Molecular mechanisms in multiple myeloma drug resistance. J Clin Pathol. 2016;69(2):97\u2013101.","journal-title":"J Clin Pathol"},{"issue":"5","key":"773_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050851","volume":"11","author":"Y Li","year":"2022","unstructured":"Li Y, Li S, Wu H. Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress. Cells. 2022;11(5): 851.","journal-title":"Cells"},{"issue":"24","key":"773_CR5","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"7","key":"773_CR6","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071\u20136.","journal-title":"Cancer Res"},{"issue":"11","key":"773_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"3","key":"773_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/leu.2014.279","volume":"29","author":"S Jagannathan","year":"2015","unstructured":"Jagannathan S, Vad N, Vallabhapurapu S, Vallabhapurapu S, Anderson KC, Driscoll JJ. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia. 2015;29(3):727\u201338.","journal-title":"Leukemia"},{"issue":"7","key":"773_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1056\/NEJMra1205406","volume":"368","author":"AM Choi","year":"2013","unstructured":"Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368(7):651\u201362.","journal-title":"N Engl J Med"},{"issue":"9","key":"773_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc.2017.53","volume":"17","author":"JMM Levy","year":"2017","unstructured":"Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528\u201342.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"773_CR11","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1158\/1535-7163.MCT-08-1177","volume":"8","author":"B Hoang","year":"2009","unstructured":"Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009;8(7):1974\u201384.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"773_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/1878-0261.12641","volume":"14","author":"J Xia","year":"2020","unstructured":"Xia J, He Y, Meng B, Chen S, Zhang J, Wu X, et al. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma. Mol Oncol. 2020;14(4):763\u201378.","journal-title":"Mol Oncol"},{"issue":"8","key":"773_CR13","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy. 2014;10(8):1380\u201390.","journal-title":"Autophagy"},{"issue":"9","key":"773_CR14","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/cas.13711","volume":"109","author":"Y Lu","year":"2018","unstructured":"Lu Y, Wang Y, Xu H, Shi C, Jin F, Li W. Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma. Cancer Sci. 2018;109(9):2706\u201316.","journal-title":"Cancer Sci"},{"issue":"12","key":"773_CR15","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.7150\/thno.15584","volume":"6","author":"M Roy","year":"2016","unstructured":"Roy M, Liang L, Xiao X, Peng Y, Luo Y, Zhou W, et al. Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma. Theranostics. 2016;6(12):2209\u201324.","journal-title":"Theranostics"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"103950","DOI":"10.1016\/j.ebiom.2022.103950","volume":"78","author":"Z Yu","year":"2022","unstructured":"Yu Z, Wei X, Liu L, Sun H, Fang T, Wang L, et al. Indirubin-3\u2019-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine. 2022;78:103950.","journal-title":"EBioMedicine"},{"issue":"3","key":"773_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bjh.13315","volume":"169","author":"Y Mishima","year":"2015","unstructured":"Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, et al. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol. 2015;169(3):423\u201334.","journal-title":"Br J Haematol"},{"issue":"46","key":"773_CR18","doi-asserted-by":"publisher","first-page":"13162","DOI":"10.1073\/pnas.1608067113","volume":"113","author":"T Hideshima","year":"2016","unstructured":"Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016;113(46):13162\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"773_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00249","volume":"9","author":"FI Huang","year":"2019","unstructured":"Huang FI, Wu YW, Sung TY, Liou JP, Lin MH, Pan SL, et al. MPT0G413, a novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma Cells. Front Oncol. 2019;9: 249.","journal-title":"Front Oncol"},{"issue":"3","key":"773_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031341","volume":"22","author":"SW Lee","year":"2021","unstructured":"Lee SW, Yeon SK, Kim GW, Lee DH, Jeon YH, Yoo J, et al. HDAC6-selective inhibitor overcomes bortezomib resistance in multiple myeloma. Int J Mol Sci. 2021;22(3): 1341.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"773_CR21","doi-asserted-by":"publisher","first-page":"BSR20181916","DOI":"10.1042\/BSR20181916","volume":"39","author":"X Sun","year":"2019","unstructured":"Sun X, Xie Y, Sun X, Yao Y, Li H, Li Z, et al. The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. Biosci Rep. 2019;39(3):BSR20181916.","journal-title":"Biosci Rep"},{"issue":"20","key":"773_CR22","doi-asserted-by":"publisher","first-page":"15280","DOI":"10.1021\/acs.jmedchem.1c01311","volume":"64","author":"Z Cao","year":"2021","unstructured":"Cao Z, Yang F, Wang J, Gu Z, Lin S, Wang P, et al. Indirubin derivatives as dual inhibitors targeting cyclin-dependent kinase and histone deacetylase for treating cancer. J Med Chem. 2021;64(20):15280\u201396.","journal-title":"J Med Chem"},{"issue":"1","key":"773_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12929-017-0374-4","volume":"24","author":"P Czerwi\u0144ska","year":"2017","unstructured":"Czerwi\u0144ska P, Mazurek S, Wiznerowicz M. The complexity of TRIM28 contribution to cancer. J Biomed Sci. 2017;24(1):63.","journal-title":"J Biomed Sci"},{"issue":"1","key":"773_CR24","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.1038\/s41467-023-41852-z","volume":"14","author":"Z Ding","year":"2023","unstructured":"Ding Z, Pan Y, Shang T, Jiang T, Lin Y, Yang C, et al. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. 2023;14(1):6269.","journal-title":"Nat Commun"},{"issue":"6","key":"773_CR25","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41418-020-00701-y","volume":"28","author":"JO Jin","year":"2021","unstructured":"Jin JO, Lee GD, Nam SH, Lee TH, Kang DH, Yun JK, et al. Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis. Cell Death Differ. 2021;28(6):1790\u2013803.","journal-title":"Cell Death Differ"},{"issue":"5","key":"773_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/15548627.2015.1034420","volume":"11","author":"CT Pineda","year":"2015","unstructured":"Pineda CT, Potts PR. Oncogenic MAGEA-TRIM28 ubiquitin ligase downregulates autophagy by ubiquitinating and degrading AMPK in cancer. Autophagy. 2015;11(5):844\u20136.","journal-title":"Autophagy"},{"key":"773_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2017.09.051","volume":"412","author":"SJ Pan","year":"2018","unstructured":"Pan SJ, Ren J, Jiang H, Liu W, Hu LY, Pan YX, et al. MAGEA6 promotes human glioma cell survival via targeting AMPK\u03b11. Cancer Lett. 2018;412:21\u20139.","journal-title":"Cancer Lett"},{"issue":"4","key":"773_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.cell.2015.01.034","volume":"160","author":"CT Pineda","year":"2015","unstructured":"Pineda CT, Ramanathan S, Fon Tacer K, Weon JL, Potts MB, Ou YH, et al. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell. 2015;160(4):715\u201328.","journal-title":"Cell"},{"issue":"30","key":"773_CR29","doi-asserted-by":"publisher","first-page":"26267","DOI":"10.1074\/jbc.R111.252569","volume":"286","author":"S Iyengar","year":"2011","unstructured":"Iyengar S, Farnham PJ. KAP1 protein: an enigmatic master regulator of the genome. J Biol Chem. 2011;286(30):26267\u201376.","journal-title":"J Biol Chem"},{"issue":"1","key":"773_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.603","volume":"12","author":"J Zhang","year":"2022","unstructured":"Zhang J, Fan X, Liao L, Zhu Y, Wan X, Rao H, et al. TRIM28 attenuates bortezomib sensitivity of hepatocellular carcinoma cells through enhanced proteasome expression. Clin Transl Med. 2022;12(1): e603.","journal-title":"Clin Transl Med"},{"issue":"3","key":"773_CR31","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.","journal-title":"Innovation (Camb)"},{"issue":"7146","key":"773_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nature05853","volume":"447","author":"UB Pandey","year":"2007","unstructured":"Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447(7146):859\u201363.","journal-title":"Nature"},{"key":"773_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.arr.2014.07.002","volume":"18","author":"JM Hyttinen","year":"2014","unstructured":"Hyttinen JM, Amadio M, Viiri J, Pascale A, Salminen A, Kaarniranta K. Clearance of misfolded and aggregated proteins by aggrephagy and implications for aggregation diseases. Ageing Res Rev. 2014;18:16\u201328.","journal-title":"Ageing Res Rev"},{"issue":"23","key":"773_CR34","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.4161\/cc.8.23.10086","volume":"8","author":"T Rzymski","year":"2009","unstructured":"Rzymski T, Milani M, Singleton DC, Harris AL. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle. 2009;8(23):3838\u201347.","journal-title":"Cell Cycle"},{"issue":"11","key":"773_CR35","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.18632\/oncotarget.3251","volume":"6","author":"M Zhang","year":"2015","unstructured":"Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, et al. Anti-\u03b2\u2082-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget. 2015;6(11):8567\u201378.","journal-title":"Oncotarget"},{"key":"773_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897862","volume":"13","author":"M Roman-Trufero","year":"2022","unstructured":"Roman-Trufero M, Auner HW, Edwards CM. Multiple myeloma metabolism - a treasure trove of therapeutic targets? Front Immunol. 2022;13: 897862.","journal-title":"Front Immunol"},{"issue":"12","key":"773_CR37","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907\u201316.","journal-title":"Blood"},{"issue":"8","key":"773_CR38","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1158\/0008-5472.CAN-07-5989","volume":"68","author":"A Rodriguez-Gonzalez","year":"2008","unstructured":"Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res. 2008;68(8):2557\u201360.","journal-title":"Cancer Res"},{"issue":"7","key":"773_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/1947601910383277","volume":"1","author":"TP Yao","year":"2010","unstructured":"Yao TP. The role of ubiquitin in autophagy-dependent protein aggregate processing. Genes Cancer. 2010;1(7):779\u201386.","journal-title":"Genes Cancer"},{"issue":"1","key":"773_CR40","doi-asserted-by":"publisher","first-page":"15142","DOI":"10.1038\/s41598-024-65937-x","volume":"14","author":"C Sun","year":"2024","unstructured":"Sun C, Zhang W, Liu H, Ding Y, Guo J, Xiong S, et al. Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification. Sci Rep. 2024;14(1):15142.","journal-title":"Sci Rep"},{"issue":"1","key":"773_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8(1):246.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"773_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13046-023-02862-3","volume":"42","author":"M Liang","year":"2023","unstructured":"Liang M, Sun Z, Chen X, Wang L, Wang H, Qin L, et al. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells. J Exp Clin Cancer Res. 2023;42(1):275.","journal-title":"J Exp Clin Cancer Res"},{"issue":"38","key":"773_CR43","doi-asserted-by":"publisher","first-page":"e2102423118","DOI":"10.1073\/pnas.2102423118","volume":"118","author":"N Agarwal","year":"2021","unstructured":"Agarwal N, Rinaldetti S, Cheikh BB, Zhou Q, Hass EP, Jones RT, et al. TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proc Natl Acad Sci U S A. 2021;118(38):e2102423118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"773_CR44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nrc3139","volume":"11","author":"S Hatakeyama","year":"2011","unstructured":"Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11(11):792\u2013804.","journal-title":"Nat Rev Cancer"},{"key":"773_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110925","volume":"112","author":"K Xu","year":"2023","unstructured":"Xu K, Li J, Li WX. Simulation of STAT and HP1 interaction by molecular docking. Cell Signal. 2023;112: 110925.","journal-title":"Cell Signal"},{"key":"773_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1431564","volume":"15","author":"K Li","year":"2024","unstructured":"Li K, Wang H, Jiang B, Jin X. TRIM28 in cancer and cancer therapy. Front Genet. 2024;15: 1431564.","journal-title":"Front Genet"},{"issue":"2","key":"773_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ygeno.2016.07.003","volume":"108","author":"H Bunch","year":"2016","unstructured":"Bunch H, Lawney BP, Burkholder A, Ma D, Zheng X, Motola S, et al. RNA polymerase II promoter-proximal pausing in mammalian long non-coding genes. Genomics. 2016;108(2):64\u201377.","journal-title":"Genomics"},{"issue":"11","key":"773_CR48","doi-asserted-by":"publisher","first-page":"e790","DOI":"10.1002\/mco2.790","volume":"5","author":"M Maghsoudloo","year":"2024","unstructured":"Maghsoudloo M, Mokhtari K, Jamali B, Gholamzad A, Entezari M, Hashemi M, et al. Multifaceted role of TRIM28 in health and disease. MedComm (2020). 2024;5(11):e790.","journal-title":"MedComm (2020)"},{"issue":"4","key":"773_CR49","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00018-020-03590-z","volume":"78","author":"C Montenegro-Venegas","year":"2021","unstructured":"Montenegro-Venegas C, Fienko S, Anni D, Pina-Fern\u00e1ndez E, Frischknecht R, Fejtova A. Bassoon inhibits proteasome activity via interaction with PSMB4. Cell Mol Life Sci. 2021;78(4):1545\u201363.","journal-title":"Cell Mol Life Sci"},{"key":"773_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101518","volume":"62","author":"N Willemsen","year":"2022","unstructured":"Willemsen N, Arigoni I, Studencka-Turski M, Kr\u00fcger E, Bartelt A. Proteasome dysfunction disrupts adipogenesis and induces inflammation via ATF3. Mol Metab. 2022;62: 101518.","journal-title":"Mol Metab"},{"issue":"1","key":"773_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13046-020-01687-8","volume":"39","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhu C, He Z, Chen S, Li L, Sun C. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p\/STAT1\/PD-L1 axis. J Exp Clin Cancer Res. 2020;39(1):179.","journal-title":"J Exp Clin Cancer Res"},{"key":"773_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.canlet.2018.05.018","volume":"430","author":"Y Li","year":"2018","unstructured":"Li Y, Huang J, Zeng B, Yang D, Sun J, Yin X, et al. PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation. Cancer Lett. 2018;430:109\u201322.","journal-title":"Cancer Lett"},{"issue":"8","key":"773_CR53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/gcc.22459","volume":"56","author":"MS Fejzo","year":"2017","unstructured":"Fejzo MS, Anderson L, Chen HW, Guandique E, Kalous O, Conklin D, et al. Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi. Genes Chromosomes Cancer. 2017;56(8):589\u201397.","journal-title":"Genes Chromosomes Cancer"},{"issue":"21","key":"773_CR54","first-page":"2599","volume":"141","author":"T Du","year":"2023","unstructured":"Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, et al. Ubiquitin receptor PSMD4\/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023;141(21):2599\u2013614.","journal-title":"Blood"},{"issue":"17","key":"773_CR55","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.1073\/pnas.1217692110","volume":"110","author":"Y Yang","year":"2013","unstructured":"Yang Y, Fiskus W, Yong B, Atadja P, Takahashi Y, Pandita TK, et al. Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proc Natl Acad Sci U S A. 2013;110(17):6841\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"773_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1016071","volume":"9","author":"V Obsilova","year":"2022","unstructured":"Obsilova V, Obsil T. Structural insights into the functional roles of 14-3-3 proteins. Front Mol Biosci. 2022;9: 1016071.","journal-title":"Front Mol Biosci"},{"issue":"9","key":"773_CR57","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1021\/acs.jmedchem.7b00574","volume":"61","author":"LM Stevers","year":"2018","unstructured":"Stevers LM, Sijbesma E, Botta M, MacKintosh C, Obsil T, Landrieu I, et al. Modulators of 14-3-3 protein-protein interactions. J Med Chem. 2018;61(9):3755\u201378.","journal-title":"J Med Chem"},{"issue":"3","key":"773_CR58","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/cdd.2010.118","volume":"18","author":"M Pozuelo-Rubio","year":"2011","unstructured":"Pozuelo-Rubio M. Regulation of autophagic activity by 14-3-3\u03b6 proteins associated with class III phosphatidylinositol-3-kinase. Cell Death Differ. 2011;18(3):479\u201392.","journal-title":"Cell Death Differ"},{"issue":"6","key":"773_CR59","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4161\/auto.19653","volume":"8","author":"JA Martina","year":"2012","unstructured":"Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012;8(6):903\u201314.","journal-title":"Autophagy"},{"issue":"6","key":"773_CR60","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/15548627.2019.1569928","volume":"15","author":"Y Xu","year":"2019","unstructured":"Xu Y, Ren J, He X, Chen H, Wei T, Feng W. YWHA\/14-3-3 proteins recognize phosphorylated TFEB by a noncanonical mode for controlling TFEB cytoplasmic localization. Autophagy. 2019;15(6):1017\u201330.","journal-title":"Autophagy"},{"issue":"3","key":"773_CR61","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/leu.2017.288","volume":"32","author":"Y Gu","year":"2018","unstructured":"Gu Y, Xu K, Torre C, Samur M, Barwick BG, Rupji M, et al. 14-3-3\u03b6 binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia. 2018;32(3):744\u201351.","journal-title":"Leukemia"},{"issue":"4","key":"773_CR62","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1182\/blood.2019004147","volume":"136","author":"Y Xu","year":"2020","unstructured":"Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, et al. YWHAE\/14-3-3epsilon expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020;136(4):468\u201379.","journal-title":"Blood"},{"issue":"18","key":"773_CR63","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.emboj.7600791","volume":"24","author":"C Wang","year":"2005","unstructured":"Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ 3rd, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. Embo J. 2005;24(18):3279\u201390.","journal-title":"Embo J"},{"key":"773_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.922675","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Cao B, Hu L, Ye J, Tian W, He X. The dual roles of MAGE-C2 in p53 ubiquitination and cell proliferation through E3 Ligases MDM2 and TRIM28. Front Cell Dev Biol. 2022;10: 922675.","journal-title":"Front Cell Dev Biol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00773-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:41:08Z","timestamp":1744202468000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00773-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00773-3","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Primary MM cells were obtained from patients with newly diagnosed multiple myeloma (NDMM) and relapsed\/refractory multiple myeloma (RRMM) who visited our hospital. The study protocol was conducted in accordance with the principles outlined in the Declaration of Helsinki and was approved by the local institutional Ethics Committees (reference number: KT2020010-EC2). Informed consent was obtained from all participants who agreed to participate in the study. The in vivo studies were performed following protocols approved by the Institutional Animal Care and Use Committee of the Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agree with the plan to publish; the contents of the manuscript; the statements on data access; to being listed as an author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}